Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Human CellExp VLDLR, human recombinant protein
VLDLR, CARMQ1, CHRMQ1, FLJ35024, VLDLRCH, VLDL-R, very-low-density-lipoprotein receptor
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P98155 |
|---|---|
| Calculated MW | This protein comprises 781 amino acids with polyhistidine tag at C-terminus and has a calculated MW of 86 kDa. The predicted N-terminus is Gly 28. DTT-reduced protein migrates as 150 & 180 kDa polypeptide in SDS-PAGE due to different glycosylation. |
| Gene ID | 7436 |
|---|---|
| Gene Symbol | VLDLR |
| Other Names | VLDLR, CARMQ1, CHRMQ1, FLJ35024, VLDLRCH, VLDL-R, very-low-density-lipoprotein receptor |
| Gene Source | Human |
| Source | HEK293 cells |
| Assay&Purity | SDS-PAGE; ≥97% |
| Assay2&Purity2 | N/A; |
| Recombinant | Yes |
| Results | Measured by its binding ability in a functional ELISA. When Recombinant Human Apolipoprotein E3 is immobilized at 1 µg/ml (100 µl/well), the concentration of Recombinant Human VLDLR that produces 50% of the optimal binding response is found to be approximately 0.03 - 0.15 µg/ml. |
| Target/Specificity | VLDLR |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| Format | Lyophilized |
| Storage | -20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The very-low-density-lipoprotein receptor (VLDL-R) is a lipoprotein receptor that shows considerable similarity to the low density-lipoprotein receptor. VLDL R is a 130 kDa type I transmembrane protein in the LDL receptor family that plays a significant role in lipid metabolism and in nervous system development and function .This receptor has been suggested to be important for the metabolism of apoprotein-E-containing triacylglycerol-rich lipoproteins, such as very-low-density lipoprotein (VLDL), beta-migrating VLDL and intermediate-density lipoprotein. It is also one of the receptors of reelin, an extracellular matrix protein which regulates the processes of neuronal migration and synaptic plasticity. In humans, the VLDL-R is encoded by the VLDLR gene. A rare neurological disorder first described in the 1970s under the name "disequilibrium syndrome" is now considered to be caused by the disruption of VLDLR gene. The disorder was renamed VLDLR-associated cerebellar hypoplasia (VLDLRCH) after a 2005 study. It is associated with parental consanguinity and found in secluded communities such as the Hutterites. VLDLRCH is one of the two known genetic disorders caused by a disruption of reelin signaling pathway, along with Norman-Roberts syndrome.
References
Gafvels M.E.,et al.Somat. Cell Mol. Genet. 19:557-569(1993).
Webb J.C.,et al.Hum. Mol. Genet. 3:531-537(1994).
Sakai J.,et al.J. Biol. Chem. 269:2173-2182(1994).
Oka K.,et al.Genomics 20:298-300(1994).
Humphray S.J.,et al.Nature 429:369-374(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
